iXBiopharma's Wafesil granted regulatory approval for treatment of male erectile dysfunction in Australia

SINGAPORE (June 19): iX Biopharma says the Australia’s regulatory authority, Therapeutic Goods Administration (TGA), has given the go-ahead for the use of Wafesil to treat of male erectile dysfunction in the country.

Wafesil, formerly known as PheoniX, is a sublingual wafer sildenafil product which comes in a new dose form of sildenafil – the active ingredient in Viagra – in dosage strengths of 25 and 50mg, and pack sizes of four, eight and 12 wafers.

It is delivered using iX Biopharma’s proprietary drug delivery technology, WaferiX, and will be supplied to market via wholesaler and pharmacy channels.

---

Related Stories

• French pharma group Sanofi announces $800 mil Singapore plant, ready in mid-2026
• Pharmesis International’s subsidiary to acquire 19% interest in Sichuan Longlife Pharmaceutical
• iX Biopharma releases updates on two of its key strategic growth drivers

---